Tag : rucaparib

Latest News

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Newsemia
Colombo, N; Oza, AM; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Weberpals, JI; … Coleman, RL; + view all Colombo, N; Oza, AM; Lorusso,...
Latest News

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

Newsemia
Oza, AM; Lorusso, D; Aghajanian, C; Oaknin, A; Dean, A; Colombo, N; Weberpals, JI; … Coleman, RL; + view all Oza, AM; Lorusso, D; Aghajanian,...
Latest News

Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France

Newsemia
BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France Source link...
Latest News

Clovis Oncology kündigt Erstattung für Rubraca®-Tabletten (Rucaparib) für Frauen mit rezidivierendem Eierstockkrebs in Italien an

Newsemia
BOULDER, Colorado–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS), hat heute bekannt gegeben, dass die italienische Arzneimittelagentur AIFA die Erstattung von Rucaparib in Italien zugelassen hat. Rucaparib...
Latest News

Clovis Oncology Highlights Rubraca® (rucaparib) Updated Data from the Ongoing TRITON2 Clinical Trial in Patients with mCRPC and Exploratory and Integrated Analyses in Recurrent Ovarian Cancer at the ESMO Congress 2019

Newsemia
BOULDER, Colo.–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) today announced updated data from the Phase 2 TRITON2 trial at the European Society for Medical Oncology (ESMO)...
Latest News

Le CHMP émet un avis positif concernant la nouvelle indication des comprimés de Rubraca®▼ (rucaparib), de Clovis Oncology, en tant que traitement d’entretien pour les femmes atteintes d’un cancer ovarien récurrent

Newsemia
BOULDER, Colorado–(BUSINESS WIRE)–Clovis Oncology, Inc. (NASDAQ: CLVS) a annoncé aujourd’hui que le comité des médicaments à usage humain (Committee for Medicinal Products for Human Use, CHMP)...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World